A New EBV Related Technologies of T Cells in Treating Malignant Tumors and Clinical Application

Nanjing Medical University

Status and phase: Unknown; Phase 2; Phase 1

Conditions: Nasopharyngeal Neoplasms

Treatments: Other: CAR-T cells

Study type: Interventional

Funder types: Other

Identifiers

NCT02980315

2016-ky-o43

Details and patient eligibility

About

The purpose of this study is to evaluate the safety of the designed LMP1-CAR -T cells and determine whether the CAR-T cells are effective in the treatment of EBV associated malignant tumors.

Full description

Half of the patients will treat with LMP1-CAR-T cells,while the other half will receive a placebo.During the time of the treatment ,we will supervise the side effect of treated group.At last we compare the survival rate and health condition of the two groups.

Enrollment: 20 estimated patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Clinical diagnosis of nasopharyngeal carcinoma

Exclusion criteria

• •pregnant woman

  • severe autoimmune diseases
  • serious infection

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

20 participants in 2 patient groups

CAR-T cells

Experimental group

Description:

the group treat with CAR-T cells

Treatment:

Other: CAR-T cells

placebo

No Intervention group

Description:

the group treat with CAR-T cells